Invesco Ltd. Grows Holdings in Liquidia Co. (NASDAQ:LQDA)

Invesco Ltd. increased its position in Liquidia Co. (NASDAQ:LQDA - Free Report) by 2,675.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 700,171 shares of the company's stock after purchasing an additional 674,940 shares during the period. Invesco Ltd. owned approximately 0.83% of Liquidia worth $8,234,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of LQDA. Steward Partners Investment Advisory LLC bought a new position in shares of Liquidia in the 4th quarter worth $59,000. EntryPoint Capital LLC bought a new position in Liquidia during the 4th quarter valued at $154,000. KLP Kapitalforvaltning AS bought a new position in Liquidia during the 4th quarter valued at $169,000. Arizona State Retirement System lifted its stake in Liquidia by 20.3% during the 4th quarter. Arizona State Retirement System now owns 15,888 shares of the company's stock valued at $187,000 after acquiring an additional 2,685 shares in the last quarter. Finally, DMC Group LLC lifted its stake in Liquidia by 17.4% during the 4th quarter. DMC Group LLC now owns 16,302 shares of the company's stock valued at $192,000 after acquiring an additional 2,419 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

Liquidia Trading Down 2.3 %

LQDA traded down $0.33 during trading on Tuesday, hitting $13.90. 139,721 shares of the company's stock traded hands, compared to its average volume of 957,002. The company's 50 day simple moving average is $14.35 and its two-hundred day simple moving average is $12.94. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.81. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -8.53 and a beta of 0.23.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The firm had revenue of $2.92 million during the quarter, compared to analysts' expectations of $4.60 million. On average, equities analysts expect that Liquidia Co. will post -1.51 EPS for the current year.

Insider Activity

In related news, CFO Michael Kaseta sold 8,283 shares of the stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $112,400.31. Following the sale, the chief financial officer now owns 396,315 shares in the company, valued at approximately $5,377,994.55. This represents a 2.05 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Roger Jeffs sold 14,130 shares of the stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $191,744.10. Following the sale, the chief executive officer now owns 1,006,420 shares in the company, valued at $13,657,119.40. The trade was a 1.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,683 shares of company stock worth $443,753 over the last 90 days. Corporate insiders own 30.10% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on LQDA shares. Scotiabank restated an "outperform" rating on shares of Liquidia in a research note on Thursday, March 20th. Needham & Company LLC restated a "buy" rating and set a $25.00 price objective on shares of Liquidia in a research note on Thursday, April 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $29.00 target price on shares of Liquidia in a research report on Thursday, March 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Liquidia presently has an average rating of "Buy" and a consensus target price of $26.63.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).